Names and pronunciation
(mye-doe-staw′-rin) Rydapt
PDF page 890
Loading InternPractice…
Drug reference
(mye-doe-staw′-rin) Rydapt
PDF page 890
Func. class.: Antineoplastic
PDF page 890
USES: Newly diagnosed FLT3 muta- tion–positive AML in combination with standard cytarabine and DAUNOrubicin induction and consolidation therapy and for the treatment of aggressive sys- temic mastocytosis, systemic mastocyto- sis with associated hematologic neo- plasm, or mast cell leukemia
PDF page 890
DOSAGE AND ROUTES Newly diagnosed FLT3 mutation– positive AML • Adult: PO 50 mg bid on days 8 to 21 of each cycle of induction therapy with cyt arabine and DAUNOrubicin; additionally, give midostaurin 50 mg bid on days 8 to 21 of each cycle of consolidation with high-dose cytarabine therapy Aggressive systemic mastocytosis, systemic mastocytosis • Adult: PO 100 mg bid until disease progression
PDF page 890
Available forms: Capsule 25 mg
PDF page 890
• Adult: PO 50 mg bid on days 8 to 21 of each cycle of induction therapy with cyt arabine and DAUNOrubicin; additionally, give midostaurin 50 mg bid on days 8 to 21 of each cycle of consolidation with high-dose cytarabine therapy Aggressive systemic mastocytosis, systemic mastocytosis
PDF page 890
• Adult: PO 100 mg bid until disease progression
PDF page 890